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in terms of health outcome as well as in terms of cost for
high-risk patients from the perspective of the individual
patient as well as of the health care payer. However, this
effect is sensitive to time of treatment start, diagnostic cer-
tainty as well as rates for hospitalisation, complication
and mortality.
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OBJECTIVE: Pneumococcical vaccine is an affective pre-
ventive intervention to prevent pneucoccical pneumonia.
In this study, cost-effectiveness of pneumococcical vacci-
nation (23 serotipes) strategies in individuals aged 5 or
more years was assessed. METHODS: Cost-effectiveness
was measured in terms of cost per life year gained (LYG),
comparing net programme costs and effectiveness. The
net programme cost was calculated from vaccinating
costs, assuming 70% compliance, less reduced health
costs from pneumococcical pneumonia achieved with the
programme. Vaccination costs were calculated taking into
account a cost of €11,51 per vaccine. Costs and beneﬁts
were estimated for 1996 using a 5% discount rate.
RESULTS: A cost-effectiveness ratio of €9.023,27 per
LYG was obtained for the universal vaccination of the
population. The cost-effectiveness ratio was €113.177,12
per LYG in individual aged 5–24 years, €19.482,51 per
LYG in those aged 25–44 years, €7.122,80 per LYG in
those aged 45–64y < 0 in those aged >64 years. In the
age group of >64 years, disease costs reduced were higher
than vaccination costs, with a savings/costs ratio of 1,58.
Results of cost-effectiveness analysis were sensitive to the
vaccine price, vaccine efﬁcacy and the percentage of pneu-
monias caused by S. pneumoniae, being less sensitive to
health costs from pneumococcical pneumonia, hospital-
ization rate in patients with a community acquired pneu-
monia and vaccination compliance. CONCLUSION:
Results obtained in this study shows that pneumococci-
cal vaccination should be a priority preventive interven-
tion in individuals aged >64 and 45–64 years.
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OBJECTIVES: For many diseases, a small number of
complicated cases accounts for the main part of the costs.
Our aim was to investigate the relevance of complications
for the overall costs of varicella in Germany in order 
to assess whether vaccination strategies targeting at risk
groups, e.g. adolescents, have the potential to sub-
stantially reduce the economic burden of varicella.
METHOD: A decision-analytic model, the Economic
Varicella VaccInation Tool for Analysis (EVITA), was
used to analyze epidemiological and economic effects of
varicella over a period of 30 years as varicella incidence
ﬂuctuates over time and, thus, a typical cost of illness
study performed in one year might provide biased esti-
mates of overall costs. Input data on the epidemiology 
of varicella and its complications as well as the respec-
tive resource use were derived from two large surveys.
RESULTS: Complications occur in 5.7% of the annual
average of 739,000 cases. Overall annual costs are €187.5
million from the societal and €78 million from the payers’
perspectives. From the payers’ (societal) perspective
32.0% (24.7%) of the overall costs can be attributed 
to complications. Complications account for 53.8%
(53.3%) of the direct medical costs and 15.5% (18.3%)
of the indirect costs. When complications occur, inpatient
care (67.7%) from the payers’ and work loss (60.9%)
from the societal perspectives are the main cost drivers 
of complications. Pneumonia accounts for the majority 
of the costs of complications. For uncomplicated 
courses of varicella, the indirect costs of work loss are 
the major cost factor. CONCLUSIONS: Complications
account for a disproportionate part of overall disease
costs. However, uncomplicated courses account for the
vast majority of costs. Vaccination strategies targeting
only on risk groups with high risks of complications
might therefore fail to substantially reduce the consider-
able economic burden of varicella.
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OBJECTIVE: In Japan, measles vaccine coverage is lower
than 80% nationwide. As a result, the number of measles
case is estimated about 100,000–200,000 a year. In this
study, we performed cost-beneﬁt analysis between the
cost of vaccination and the cost of treatment of measles.
Although cost effectiveness analysis including cost-beneﬁt
analysis of vaccination is extensively performed (e.g.
inﬂuenza), it is not carried out concerning measles at all.
This research is unique in this point of view. METHODS:
We conducted chart investigation of 291 measles patients
(171 outpatient cases and 120 hospitalization cases) in
one hospital from July 1997 to September 2001. Among
them, medical expenses were calculated about 121
samples of outpatients and 112 inpatients which are 
considered to be appropriate for the contents of medical
treatment. At the same time, we estimated opportunity
